BTG (LSE: BTG) today announced the first successful implantation of its Sentry bioconvertible inferior vena cava (IVC) filter in patients outside of a clinical trial.
The Sentry device won FDA 510(k) clearance in 2017. London-based BTG acquired the device in September through its purchase of Galway, Ireland–based Novate.
Get the full story on our sister site Medical Design & Outsourcing.
The post BTG’s bioconvertible IVC filter implanted in Arizona patients appeared first on MassDevice.
from MassDevice https://ift.tt/2RyxQLZ
Cap comentari:
Publica un comentari a l'entrada